Articles related to HIV
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
The recent phase 3 trial on pitavastatin’s effectiveness in HIV-infected patients opens new avenues in cardiovascular disease prevention within this demographic. Physicians may find the detailed insights on risk reduction and side effects beneficial in tailoring personalized care strategies.
Allergy & Immunology July 31st 2023
Access to a Novel First-line Single-tablet HIV Antiretroviral Regimen in Affordable Care Act Marketplace Plans, 2018–2020
Single-tablet regimen (STR) coverage under qualified health plans (QHPs) varies widely across the US. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) coverage has grown over time, many QHPs in priority jurisdictions for the Ending the HIV Epidemic (EHE) have coinsurance requirements. Delay in QHP coverage and benefit design may hinder access to new antiretroviral treatment (ART) regimens.
Allergy & Immunology April 27th 2023
MKSAP Quiz: Evaluation for Fatigue, Headache
Other than anterior cervical and occipital lymphadenopathy, the physical examination and vitals are unremarkable. The patient is also requesting HIV pre-exposure prophylaxis initiation. HIV testing negative. What’s the best management?
Family Medicine/General Practice April 12th 2023
Sunlenca Approved for Patients with Multidrug-Resistant HIV-1 Infection
Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.
Allergy & Immunology January 11th 2023
IDWeek 2022 Study Bites: What’s New in HIV Antiretroviral Therapy
A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.
Internal Medicine December 7th 2022
A Persistent Challenge: Managing HIV Multidrug Resistance
After completing this activity, participants will be better equipped to discuss the major difficulties in managing MDR HIV and to illustrate the promise of both existing and forthcoming MDR HIV medicines.
Clinical Pharmacology September 8th 2022